Cargando…

Correction to: Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab

Detalles Bibliográficos
Autores principales:	Chen, Gang, Kronenberger, Peter, Teugels, Erik, Umelo, Ijeoma Adaku, De Grève, Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995100/ https://www.ncbi.nlm.nih.gov/pubmed/32005236 http://dx.doi.org/10.1186/s12916-020-1501-8

Ejemplares similares

Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
por: Chen, Gang, et al.
Publicado: (2012)

Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib
por: Chen, Gang, et al.
Publicado: (2013)

Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer
por: Noor, Alfiah, et al.
Publicado: (2018)

miR-146a Inhibits Cell Growth, Cell Migration and Induces Apoptosis in Non-Small Cell Lung Cancer Cells
por: Chen, Gang, et al.
Publicado: (2013)

Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade
por: Umelo, Ijeoma Adaku, et al.
Publicado: (2015)

Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells
por: Chen, Gang, et al.
Publicado: (2010)

Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer
por: Umelo, Ijeoma, et al.
Publicado: (2015)

Stromal Modulators of TGF-β in Cancer
por: Costanza, Brunella, et al.
Publicado: (2017)

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors
por: Fischel, J-L, et al.
Publicado: (2005)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Correction to: Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features
por: Shirley, Matt
Publicado: (2021)

Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?
por: De Greve, Jacques, et al.
Publicado: (2020)

Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
por: Chen, Qi, et al.
Publicado: (2015)

Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors
por: Rozensztajn, Nathalie, et al.
Publicado: (2014)

Correction to: Role of Bruton’s tyrosine kinase in B cells and malignancies
por: Pal Singh, Simar, et al.
Publicado: (2019)

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
por: Le, Xiuning, et al.
Publicado: (2023)

Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer
por: Noeparast, Amir, et al.
Publicado: (2018)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients with Advanced Non-Small Cell Lung Cancer
por: Meriggi, F., et al.
Publicado: (2010)

Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Lee, Jae Cheol, et al.
Publicado: (2013)

Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer
por: Gao, Yuan, et al.
Publicado: (2015)

Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment
por: Liang, Hongge, et al.
Publicado: (2018)

Fluorescence Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer
por: Martin-Fernandez, Marisa L.
Publicado: (2022)

Correction to: Randomized trial of First-Line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-Mutated Non-Small cell lung cancer
Publicado: (2023)

Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
por: James, Angela Joubert, et al.
Publicado: (2021)

Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2019)

EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas
por: Nelhűbel, Györgyi A., et al.
Publicado: (2021)

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues
por: Bencardino, K., et al.
Publicado: (2007)

Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure
por: Kawamura, Takahisa, et al.
Publicado: (2016)

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
por: Barnes, Tristan A., et al.
Publicado: (2017)

Management of non-small cell lung cancer with resistance to epidermal growth factor receptor tyrosine kinase inhibitor: case discussion
por: Zheng, Yuyan, et al.
Publicado: (2020)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor
por: Kim, Woo-Jin, et al.
Publicado: (2015)

Molecular Basis of Drug Resistance: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Anaplastic Lymphoma Kinase Inhibitors
por: Yang, Sei-Hoon
Publicado: (2013)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitor in the treatment of patients with nonsmall cell lung cancer
por: Li, Xi, et al.
Publicado: (2023)

Targeting mTOR to Overcome Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer Cells
por: Fei, Shi-Jiang, et al.
Publicado: (2013)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance
por: Heydt, Carina, et al.
Publicado: (2018)

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?
por: Tabbò, Fabrizio, et al.
Publicado: (2020)

Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
por: Chikaishi, Yasuhiro, et al.
Publicado: (2020)

Correction: The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer
por: Allen, Joshua E., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_p7ljkumvkjimngvnsnv6fukk8n